NCT04999761 2024-09-25AB122 Platform StudyTaiho Pharmaceutical Co., Ltd.Phase 1 Recruiting917 enrolled
NCT02443324 2024-07-31A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract CancerEli Lilly and CompanyPhase 1 Completed175 enrolled 23 charts